Why Is Dyne Therapeutics Stock Soaring On Monday?
Why Is Dyne Therapeutics Stock Soaring On Monday?
DYNE-101 demonstrated an improvement in myotonia as measured by video hand opening time (vHOT) in all reported cohorts. Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
週一，達因療法公司（納斯達克股票代碼：DYN）公佈了其正在進行的針對1型肌強直性營養不良症（DM1）患者的 DYNE-101 1/2期ACHIEVE試驗，以及正在進行的針對願意跳過外顯子51的杜興氏肌肉萎縮症（DMD）患者的 DYNE-251 1/2期DELIVER試驗的臨床數據。
Earlier this year, Dyne Therapeutics released initial clinical data from both trials.
今年早些時候，達因療法發佈了這兩項試驗的初步臨床數據。
In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splicing correction.
在ACHIEVE試驗中，5.4 mg/kg Q8W隊列的患者在3個月時在廣泛的22個基因組中平均剪接校正率爲基線的27％，所有參與者均表現出剪接校正。
DYNE-101 demonstrated an improvement in myotonia as measured by video hand opening time (vHOT) in all reported cohorts.
根據所有報告的隊列的視頻手部開啓時間（VHOT）來衡量，DYNE-101 顯示出肌張力有所改善。
The 1.8 mg/kg Q4W group had a mean 3.1-second benefit in myotonia at 3 months, increasing to 4.4 seconds at 12 months.
1.8 mg/kg Q4W 組在 3 個月時肌張力受益平均爲 3.1 秒，在 12 個月時增加到 4.4 秒。
In addition, the 5.4 mg/kg Q8W cohort had a mean 4.5-second improvement in myotonia at 3 months.
此外，5.4 mg/kg Q8W隊列在3個月時肌張力平均改善了4.5秒。
DYNE-101 demonstrated an improvement in muscle strength and early and sustained potential benefit in the 10-meter Walk/Run Test and 5-times to Stand Test.
在 10 米步行/跑步測試和 5 次站立測試中，DYNE-101 顯示肌肉力量有所改善，並有早期和持續的潛在益處。
Dyne reported efficacy data from 8 male patients with DMD amenable to exon 51 skipping enrolled in the 10 mg/kg (approximate PMO dose) cohort of the randomized, placebo-controlled MAD portion of the DYNE-251 DELIVER trial.
達因報告了8名跳過外顯子51的男性患者的療效數據，這些患者加入了 DYNE-251 DELIVER 試驗隨機、安慰劑對照的 MAD 部分 10 mg/kg（大約 PMO 劑量）隊列中。
10 mg/kg of DYNE-251 Q4W demonstrated dose-dependent exon skipping and dystrophin expression.
10 mg/kg 的 DYNE-251 Q4W 表現出劑量依賴性外顯子跳躍和肌營養不良蛋白表達。
DYNE-251 reached levels of dystrophin expression that exceeded levels reported in a clinical trial for the current weekly standard of care for DMD exon 51, eteplirsen, at 6 months1 with a 12-fold lower PMO dose.
DYNE-251 在 6 個月時達到的肌萎縮蛋白表達水平超過了當前 DMD 外顯子 51 每週護理標準 eteplirsen 的臨床試驗中報告的水平，PMO 劑量降低了 12 倍。
DYNE-251 also demonstrated encouraging trends in multiple functional endpoints.
DYNE-251 在多功能終端方面也顯示出令人鼓舞的趨勢。
Patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change (unadjusted for muscle content) from baseline at 6 months.
接受10 mg/kg DYNE-251 Q4W治療的患者的平均絕對肌萎縮素水平爲正常水平的3.22％，與基線相比在6個月時變化2.97％（未調整肌肉含量）。
Eteplirsen reached a mean absolute unadjusted dystrophin level of 0.30% of normal and a 0.06% change from baseline at 6 months.
Eteplirsen在6個月時達到了未經調整的平均絕對肌營養素水平爲正常值的0.30％，與基線相比變化了0.06％。
When adjusting for muscle content, the DYNE-251 treated group reached 7.64% mean absolute dystrophin, greater than levels reported by peptide conjugate PMOs in clinical development.
調整肌肉含量時，DYNE-251 治療組的平均絕對肌營養不良蛋白達到了 7.64%，高於肽偶聯物 pMO 在臨床開發中報告的水平。
Trends in improvement were observed in multiple functional endpoints in the 10 mg/kg DYNE-251 Q4W group at 6 months.
在 10 mg/kg DYNE-251 Q4W 組中，在 6 個月時觀察到多個功能終點的改善趨勢。
Price Action: DYN shares are up 27.80% at $35.36 at the last check Monday.
價格走勢：週一最後一次檢查時，DYN股價上漲27.80％，至35.36美元。
譯文內容由第三人軟體翻譯。